Paola Ulivi

Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Matteo Canale, Elisabetta Petracci, Angelo Delmonte et al. · Clinical Cancer Research · 2016 · 297 citations · Full text

Medicine, Oncology, Pharmacology +16

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs

Francesco� Fabbri, Silvia Carloni, Wainer Zoli et al. · Cancer Letters · 2013 · 220 citations

Medicine, Biomedical Engineering, Oncology +17

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

Mara Bonelli, Graziana Digiacomo, Claudia Fumarola et al. · Neoplasia · 2017 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy

Paola Ulivi, Elisa Chiadini, Claudio Dazzi et al. · Clinical Lung Cancer · 2015 · 89 citations

Medicine, Molecular Genetics, Oncology +14

Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines

Wainer Zoli, Paola Ulivi, Anna Tesei et al. · Breast Cancer Research · 2005 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17